Nurse Practitioner, Family · Houston, TX
NPI
1568142479
Since 2023
Specialty
Nurse Practitioner, Family
Code 363LF0000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
1515 Holcombe Blvd
Houston, TX, 77030
Phone (713) 792-8666
Groups this clinician bills Medicare through
Medicare paid, 2024
$6,789
151 services
Medicare patients, 2024
113
Average age 73
Drug cost, 2024
$5.4M
922 prescriptions
Company payments, 2025
$890
From 22 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Emily M Parkman was code 99213 (office e&m - established), 72 times for 52 patients. In total Emily M Parkman billed 151 services in 9 codes, and Medicare paid $6,789.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-07-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Facility | 72 | 52 | $42.71 | $3,075 |
| 38222 Other Organ Systems | Facility | 38 | 38 | $46.90 | $1,782 |
| 99214 Office E&M - Established | Facility | 14 | 12 | $65.80 | $921 |
By year: 2023 $1,889 for 43 services; 2024 $6,789 for 151 services.
Medicare prescription drug claims, 2024
In 2024, the drug Emily M Parkman prescribed most often to Medicare patients was Jakafi (Ruxolitinib Phosphate), with 189 prescriptions and refills. In total Emily M Parkman wrote 922 Medicare prescriptions that cost $5.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Jakafi Ruxolitinib Phosphate | 189 | 189 | 26 | $3.2M |
| Hydroxyurea Generic | 34 | 82 | 12 | $1,163 |
| Methylprednisolone Generic | 31 | 31 | 28 | $160 |
| Fluticasone Propionate Generic | 28 | 46 | 27 | $230 |
| Valacyclovir Valacyclovir Hcl | 27 | 47 | 11 | $995 |
| Ojjaara Momelotinib Dihydrochloride | 24 | 24 | Under 11 | $629K |
| Allopurinol Generic | 21 | 47 | Under 11 | $179 |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | 19 | 19 | 17 | $180 |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | 15 | 15 | 11 | $142 |
| Ondansetron Odt Ondansetron | 15 | 15 | Under 11 | $171 |
| Besremi Ropeginterferon Alfa-2b-Njft | 14 | 14 | Under 11 | $171K |
| Levofloxacin Generic | 14 | 18 | Under 11 | $203 |
| Venclexta Venetoclax | 13 | 13 | Under 11 | $180K |
| Fluconazole Generic | 13 | 17 | Under 11 | $937 |
| Estradiol Generic | 12 | 23 | Under 11 | $736 |
Brand drugs: 356 claims; generic drugs: 566 claims; opioid claims: 19.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Emily M Parkman $890 ($890 in general payments such as food, travel and fees) from 22 companies. The largest payer was Abbvie Inc. with $147.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 9 | $147 |
| Novo Nordisk Inc NVO | 4 | $87.64 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 3 | $58.58 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 3 | $56.9 |
| Astellas Pharma US Inc 4503.T | 2 | $51.05 |
| Lilly USA, LLC LLY | 3 | $48.1 |
| Xeris Pharmaceuticals, Inc. | 2 | $39.65 |
| Acella Pharmaceuticals, LLC | 2 | $39.51 |
| GlaxoSmithKline, LLC. GSK | 2 | $37.34 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $37.18 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.